333 related articles for article (PubMed ID: 15644430)
21. Impaired Itching Perception in Murine Models of Cholestasis Is Supported by Dysregulation of GPBAR1 Signaling.
Cipriani S; Renga B; D'Amore C; Simonetti M; De Tursi AA; Carino A; Monti MC; Sepe V; Zampella A; Fiorucci S
PLoS One; 2015; 10(7):e0129866. PubMed ID: 26177448
[TBL] [Abstract][Full Text] [Related]
22. Disrupted coordinate regulation of farnesoid X receptor target genes in a patient with cerebrotendinous xanthomatosis.
Honda A; Salen G; Matsuzaki Y; Batta AK; Xu G; Hirayama T; Tint GS; Doy M; Shefer S
J Lipid Res; 2005 Feb; 46(2):287-96. PubMed ID: 15576845
[TBL] [Abstract][Full Text] [Related]
23. Bile acid signaling through FXR induces intracellular adhesion molecule-1 expression in mouse liver and human hepatocytes.
Qin P; Borges-Marcucci LA; Evans MJ; Harnish DC
Am J Physiol Gastrointest Liver Physiol; 2005 Aug; 289(2):G267-73. PubMed ID: 15817812
[TBL] [Abstract][Full Text] [Related]
24. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
[TBL] [Abstract][Full Text] [Related]
25. Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.
Ho PP; Steinman L
Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1600-5. PubMed ID: 26811456
[TBL] [Abstract][Full Text] [Related]
26. Protective effects of yangonin from an edible botanical Kava against lithocholic acid-induced cholestasis and hepatotoxicity.
Kong Y; Gao X; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Sun P; Meng Q
Eur J Pharmacol; 2018 Apr; 824():64-71. PubMed ID: 29427579
[TBL] [Abstract][Full Text] [Related]
27. Dietary cholesterol stimulates CYP7A1 in rats because farnesoid X receptor is not activated.
Xu G; Pan LX; Li H; Shang Q; Honda A; Shefer S; Bollineni J; Matsuzaki Y; Tint GS; Salen G
Am J Physiol Gastrointest Liver Physiol; 2004 May; 286(5):G730-5. PubMed ID: 14684380
[TBL] [Abstract][Full Text] [Related]
28. Bile acid nuclear receptor FXR and digestive system diseases.
Ding L; Yang L; Wang Z; Huang W
Acta Pharm Sin B; 2015 Mar; 5(2):135-44. PubMed ID: 26579439
[TBL] [Abstract][Full Text] [Related]
29. Beneficial effects of colchicine on 17alpha-ethynylestradiol-induced cholestasis in rats.
Zhou ZX; Wang T; Jiang ZZ; Shang J; Liu L; Zhang Y; Zhu D; Huang X; Zhang S; Hu Y; Wang JY; Zhang LY
Arzneimittelforschung; 2011; 61(3):173-9. PubMed ID: 21528642
[TBL] [Abstract][Full Text] [Related]
30. ATP8B1 deficiency disrupts the bile canalicular membrane bilayer structure in hepatocytes, but FXR expression and activity are maintained.
Cai SY; Gautam S; Nguyen T; Soroka CJ; Rahner C; Boyer JL
Gastroenterology; 2009 Mar; 136(3):1060-9. PubMed ID: 19027009
[TBL] [Abstract][Full Text] [Related]
31. Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver.
Zollner G; Wagner M; Fickert P; Geier A; Fuchsbichler A; Silbert D; Gumhold J; Zatloukal K; Kaser A; Tilg H; Denk H; Trauner M
Am J Physiol Gastrointest Liver Physiol; 2005 Nov; 289(5):G798-805. PubMed ID: 16002565
[TBL] [Abstract][Full Text] [Related]
32. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.
Pellicciari R; Costantino G; Camaioni E; Sadeghpour BM; Entrena A; Willson TM; Fiorucci S; Clerici C; Gioiello A
J Med Chem; 2004 Aug; 47(18):4559-69. PubMed ID: 15317466
[TBL] [Abstract][Full Text] [Related]
33. Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity.
Yu J; Lo JL; Huang L; Zhao A; Metzger E; Adams A; Meinke PT; Wright SD; Cui J
J Biol Chem; 2002 Aug; 277(35):31441-7. PubMed ID: 12052824
[TBL] [Abstract][Full Text] [Related]
34. Chenodeoxycholic acid-mediated activation of the farnesoid X receptor negatively regulates hydroxysteroid sulfotransferase.
Miyata M; Matsuda Y; Tsuchiya H; Kitada H; Akase T; Shimada M; Nagata K; Gonzalez FJ; Yamazoe Y
Drug Metab Pharmacokinet; 2006 Aug; 21(4):315-23. PubMed ID: 16946559
[TBL] [Abstract][Full Text] [Related]
35. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis.
Liu Y; Binz J; Numerick MJ; Dennis S; Luo G; Desai B; MacKenzie KI; Mansfield TA; Kliewer SA; Goodwin B; Jones SA
J Clin Invest; 2003 Dec; 112(11):1678-87. PubMed ID: 14623915
[TBL] [Abstract][Full Text] [Related]
36. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo.
Rizzo G; Disante M; Mencarelli A; Renga B; Gioiello A; Pellicciari R; Fiorucci S
Mol Pharmacol; 2006 Oct; 70(4):1164-73. PubMed ID: 16778009
[TBL] [Abstract][Full Text] [Related]
37. Targeting FXR in cholestasis: hype or hope.
Fiorucci S; Distrutti E; Ricci P; Giuliano V; Donini A; Baldelli F
Expert Opin Ther Targets; 2014 Dec; 18(12):1449-59. PubMed ID: 25200104
[TBL] [Abstract][Full Text] [Related]
38. 3alpha-6alpha-Dihydroxy-7alpha-fluoro-5beta-cholanoate (UPF-680), physicochemical and physiological properties of a new fluorinated bile acid that prevents 17alpha-ethynyl-estradiol-induced cholestasis in rats.
Clerici C; Castellani D; Asciutti S; Pellicciari R; Setchell KD; O'Connell NC; Sadeghpour B; Camaioni E; Fiorucci S; Renga B; Nardi E; Sabatino G; Clementi M; Giuliano V; Baldoni M; Orlandi S; Mazzocchi A; Morelli A; Morelli O
Toxicol Appl Pharmacol; 2006 Jul; 214(2):199-208. PubMed ID: 16487557
[TBL] [Abstract][Full Text] [Related]
39. Picroside II alleviates liver injury induced by alpha-naphthylisothiocyanate through AMPK-FXR pathway.
Li T; Zheng R; Xu L; Zhou M; Wang X; Guo Q; Ji H; Li L
Toxicol Appl Pharmacol; 2020 Dec; 408():115248. PubMed ID: 32976922
[TBL] [Abstract][Full Text] [Related]
40. The nuclear hormone receptor farnesoid X receptor (FXR) is activated by androsterone.
Wang S; Lai K; Moy FJ; Bhat A; Hartman HB; Evans MJ
Endocrinology; 2006 Sep; 147(9):4025-33. PubMed ID: 16675527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
